Immunotherapy boost before surgery shows promise for tough bladder cancers
NCT ID NCT02690558
Summary
This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy could better shrink tumors before bladder removal surgery. It involved 39 adults with muscle-invasive bladder cancer who were scheduled for surgery. The goal was to see if this three-drug combination could reduce the cancer stage more effectively than chemotherapy alone, potentially improving long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
North Carolina Cancer Hospital (UNC)
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.